summary
Introduced
01/09/2020
01/09/2020
In Committee
01/09/2020
01/09/2020
Crossed Over
Passed
Dead
12/31/2020
12/31/2020
Introduced Session
116th Congress
Bill Summary
A BILL To amend the Federal Food, Drug, and Cosmetic Act to restrict direct-to-consumer drug advertising. 1
AI Summary
This bill, the Responsibility in Drug Advertising Act of 2020, amends the Federal Food, Drug, and Cosmetic Act to restrict direct-to-consumer drug advertising. The key provisions are: 1) A 3-year ban on direct-to-consumer advertising for new drugs, with a possible waiver in the third year if the Secretary of Health and Human Services determines it would have an affirmative value to public health; 2) The Secretary may prohibit direct-to-consumer advertising of a drug after the initial 3-year period if significant adverse health effects are identified; and 3) The Secretary must revise regulations to implement these changes within 1 year. The bill aims to limit premature advertising of new drugs before their risks and benefits are fully understood.
Committee Categories
Health and Social Services
Sponsors (1)
Last Action
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (on 01/09/2020)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.congress.gov/bill/116th-congress/senate-bill/3180/all-info |
| BillText | https://www.congress.gov/116/bills/s3180/BILLS-116s3180is.pdf |
| Bill | https://www.congress.gov/116/bills/s3180/BILLS-116s3180is.pdf.pdf |
Loading...